ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6069 articles about ACCESSWIRE
-
Pressure BioSciences Continues Expansion of IP Portfolio of Revolutionary UltraShear Technology with Award of First Canadian Patent
10/10/2023
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today announced the award of the first Canadian patent for its revolutionary UltraShearTM Technology (UltraShearTM or USTTM) platform.
-
Berlin Cures takes next step in battle against Long COVID
10/10/2023
Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies, is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.
-
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
10/10/2023
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, announced that over 400,000 of its ADRs are now outstanding.
-
IRLAB Signs Phase III Regulatory US Consultants to Support Preparation for Mesdopetam’s end-of-Phase 2 Meeting with the US FDA
10/10/2023
IRLAB Therapeutics IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson's disease, announced that the company has secured top expertise in supporting the preparations for Phase III with mesdopetam.
-
MilliporeSigma Partner Beyond Benign Launches New Green Chemistry Teaching and Learning Community Online Platform
10/10/2023
Global green chemistry education nonprofit Beyond Benign has launched its Green Chemistry Teaching and Learning Community free online platform to help the green chemistry community around the world connect and learn together.
-
IRLAB to present at Redeye Neurology Theme Event on October 11, 2023
10/10/2023
IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 10, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will present at Redeye Neurology Theme Event on Wednesday, October 11, 2023.
-
Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference
10/10/2023
Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.
-
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
10/10/2023
Salix Pharmaceuticals today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021.
-
Edesa Biotech Announces One-for-Seven Reverse Share Split
10/10/2023
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, is announcing that it intends to effect a one-for-seven reverse share split of its common shares.
-
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
10/9/2023
Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.
-
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
10/9/2023
Protagonist Therapeutics, Inc. announced that the company will be eligible to receive $60M in milestone payments in the fourth quarter for the advancement of JNJ-2113 into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company, the Company's partner in the development of JNJ-2113.
-
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
10/6/2023
enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it has achieved full enrollment in SAVVE®️, the 75 person U.S. pivotal trial for the VenoValve®️ and the final precursor for seeking FDA pre-market approval of the VenoValve.
-
GENZEVA and RYLTI Partner to Develop a Groundbreaking Application to More Clearly Understand the Molecular Mechanisms of Disease
10/6/2023
Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, has partnered with tech innovator RYLTI to develop an innovative groundbreaking application of AI Knowledge Engineering and use of a biomimetic digital twin ecosystem for advanced genomic research.
-
XVIVO Perfusion AB Announces Conference call on Interim Report
10/6/2023
XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report July-September 2023.
-
Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)
10/5/2023
The shareholders of Spago Nanomedical AB, corporate registration number 556574-5048 are hereby summoned to the Extraordinary General Meeting on Tuesday 31 October 2023, at 13.00 p.m. CET at Advokatfirman Cederquist's premises, Hovslagargatan 3, in Stockholm.
-
Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development
10/5/2023
Zomedica Corp., a veterinary health company offering diagnostic and therapeutic devices for companion animals, announced the acquisition of Qorvo Biotechnologies LLC, creators of the OmniaTM and TRUFORMA® point of care diagnostic platforms.
-
FSD Pharma and Celly Nu Enter Into Arrangement Agreement
10/5/2023
FSD Pharma Inc. and Celly Nutrition Corp. announced today that they have entered into a definitive arrangement agreement dated October 4, 2023 (with respect to the distribution of a portion of FSD Pharma's shareholdings of Celly Nu to certain securityholders of FSD Pharma (the "Transaction").
-
Birch Concepts LLC Unveils the Innovative Soviflex Self-Retaining Vaginal Retractor
10/5/2023
The Soviflex™ self-retaining vaginal retractor is a revolutionary device designed to improve the repair of vaginal lacerations caused by childbirth.
-
Report from the Extraordinary General Meeting of Promore Pharma AB held on 5 October 2023
10/5/2023
Promore Pharma AB, reg. no. 556639-6809, held an extraordinary general meeting on Thursday, 5 October 2023.
-
New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients
10/5/2023
Diagnostic company SphingoTec GmbH announces that a new, improved formula has been developed for estimating the GFR using its kidney function biomarker penKid.